Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DA-13-007
- Development stage
- Unknown
- Lead developer
- Derm Avance
- Administration
- Injection
01
Overview
DA-13-007 is a patent-protected, second-generation dermal filler developed for aesthetic medicine. It is designed to reduce or eliminate wrinkles and restore soft tissue volume lost due to aging, thereby returning the dermis to a more youthful state. DA-13-007 is positioned amongst market leaders such as Juvederm, Restylane, Radiesse, and Sculptra, but represents a new, proprietary technology in the dermal filler category. The mechanism of action is mechanical augmentation via subdermal injection, replacing lost volume; no drug-target activity or systemic pharmacological effect is intended[3].
- Brand names
- DA-13-007-Dermal FillerDA13-007-Dermal FillerDA 13-007-Dermal Filler
- Other names
- DA-13-007DA13-007DA 13-007
Beyond the preview
Go deeper on DA-13-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DA-13-007.